Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhPDGF-BB Gel in Deep Second-Degree Burn Wounds
CTR20255194Phase 3Active
- Sponsor
- Huaren Biotech
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of becaplermin in burn injury, thermal injury, deep partial-thickness burn, sponsored by Huaren Biotech. Started May 2026; status: active.
02
Drugs
becaplermin
03
Conditions
burn injurythermal injurydeep partial-thickness burn
Beyond the preview
Go deeper on CTR20255194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255194.